North Ryde, Australia Clinical Trials

A listing of North Ryde, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
A Study of Apalutamide in Participants With High-Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS), as compared to placebo …

cancer
metastasis
antiandrogen therapy
prostatectomy
apalutamide
Northern Cancer Institute
 (4.8 away) Contact site
  • 291 views
  • 22 Nov, 2020
  • +349 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP plus placebo.

Macquarie University
 (1.3 away) Contact site
  • 498 views
  • 15 Oct, 2020
  • +479 other locations
Safety Tolerability Pharmacokinetics and Efficacy of AMG 160 in Subjects With mCRPC

A study to evaluate the safety and tolerability of AMG 160 and in combination with pembrolizumab in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

gonadorelin
antiandrogen therapy
castration-resistant prostate cancer
prostate specific antigen
bilateral orchidectomy
Research Site
 (7.5 away) Contact site
  • 217 views
  • 04 Dec, 2020
  • +17 other locations
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (< 50 nanograms/deciliter [ng/dL]) in participants with androgen-sensitive advanced prostate cancer.

metastasis
leuprolide
testosterone
prostatectomy
adenocarcinoma
Wahroonga
 (5.1 away) Contact site
  • 1590 views
  • 04 Nov, 2020
  • +351 other locations
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary …

antiandrogen therapy
abiraterone
androgen suppression
prednisone
enzalutamide
Site AU61004
 (7.7 away) Contact site
  • 1404 views
  • 05 Dec, 2020
  • +130 other locations
Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C 2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C 1%)

To establish a minimum of 6 months of prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study. To establish a minimum of 6 months of prospective …

gene therapy
Factor VIII
christmas disease
antihemophilic factor
hemophilia
Royal Prince Alfred Hospital
 (7.6 away) Contact site
  • 210 views
  • 22 Oct, 2020
  • +78 other locations
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Primary Objective: To characterize the frequency of bleeding episodes while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor or bypassing agent (BPA) prophylaxis Secondary Objectives: To characterize the following while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis: the frequency of spontaneous bleeding …

christmas disease
hemarthrosis
immune tolerance induction
severe haemophilia a
factor ix
Investigational Site Number 6101
 (7.6 away) Contact site
  • 312 views
  • 11 Nov, 2020
  • +55 other locations
Study of SRP-4045 and SRP-4053 in DMD Patients

The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.

corticosteroids
muscular dystrophy
deletion mutation
forced vital capacity
Children's Hospital at Westmead
 (7.7 away) Contact site
  • 0 views
  • 15 Jul, 2020
  • +73 other locations
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Chris O'Brien Lifehouse
 (7.3 away) Contact site
  • 4293 views
  • 04 Nov, 2020
  • +477 other locations
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce genetic material into cells to compensate …

gene therapy
factor ix activity
hemophilia
Royal Prince Alfred Hospital
 (7.3 away) Contact site
  • 37 views
  • 16 Nov, 2020
  • +38 other locations